TAI Diagnostics develops and commercializes cell-free DNA (cfDNA) transplant monitoring technology licensed from the Medical College of Wisconsin. Its TAI test uses a small blood sample to identify and quantify donor-specific cfDNA as a direct measure of organ injury. The company was founded in 2015 and is led by CEO Frank Langley; inventors and founders include Dr. Michael Mitchell and Dr. Aoy Tomita-Mitchell. TAI intends to use recent proceeds for ongoing R&D, clinical studies, and the upcoming commercial launch of post-transplant monitoring assays performed by its CLIA- and CAP-accredited reference laboratory. The company has raised over $21M since inception and closed a $10M Series A equity financing. It has also entered into a collaboration agreement with United Therapeutics Corporation. TAI Diagnostics develops and commercializes patented cell-free DNA technology licensed from the Medical College of Wisconsin for monitoring transplanted solid organs. The company's initial focus is monitoring heart transplant patients, with plans to further develop the cfDNA technology for other transplanted organs. Founded in 2015 by Dr. Michael Mitchell and Dr. Aoy Tomita-Mitchell, the founders have backgrounds in pediatric cardiothoracic surgery and academic research. The company is based in Milwaukee. It plans to use financing to continue R&D, conduct clinical studies, and establish a reference lab to offer its post-transplant monitoring assays. In conjunction with the financing, Frank Langley joined the company as chief executive officer.

Total raised

$18M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2018